Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases

Journal of Neuroimmunology

Volumn 129, Issue 1-2, 2002, Pages 216-223

  Garcia Monco, Juan Carlos ^a   Coleman, James L ^b   Benach, Jorge L ^b  

^a HOSPITAL DE GALDAKAO   (Spain)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

suPAR; uPAR; Urokinase; Urokinase receptor

Indexed keywords

ALBUMIN; PLASMINOGEN; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN INJURY; CARCINOMATOUS MENINGITIS; CELL INVASION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CHEMOTAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMYELINATING DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME; PERIPHERAL NEUROPATHY; PERMEABILITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SERUM; STROKE; VIRUS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; CELL COUNT; CELL MOVEMENT; CEREBROSPINAL FLUID PROTEINS; CHEMOTAXIS, LEUKOCYTE; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; RECEPTORS, CELL SURFACE; UP-REGULATION;

EID: 0036344642     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00186-8     Document Type: Article

References (45)

1. Tissue plasminogen activator gene expression in multiple sclerosis brain tissue
2. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice
3. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system
4. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer
5. Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87)
6. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
7. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
8. Differential cellular accumulation of transforming growth factor-beta1, -beta2, and -beta3 in brains of patients who died with cerebral malaria
9. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R
10. Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria
11. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases
12. Serine proteases and brain damage - Is there a link?
13. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage
14. Urokinase is required for T lymphocyte proliferation and activation in vitro
15. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage
16. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain
17. A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas
18. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix
19. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
20. CD27 and (TNFR) relatives in the immune system: Their role in health and disease
21. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
22. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer
23. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors
24. Structure and function of the urokinase receptor
25. Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor
26. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy
27. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy
28. Perturbation of the integrity of the blood-brain barrier by fibrinolytic enzymes
29. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification
30. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients
31. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
32. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
33. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
34. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein
35. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect
36. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R
37. N-formylmethionyl peptides as chemoattractants for leucocytes
38. Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients
39. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection
40. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients
41. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients
42. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
43. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e
44. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase
45. The plasminogen activator/plasmin system